インディアナ州におけるクローン病の臨床試験
インディアナ州内の拠点で、クローン病に関する13件の研究が参加者を募集しています。
インディアナ州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
被験者募集中第3相
3歳以上 · 全性別 · 2026/09/25更新 · NCT06663332Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/09/23更新 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/08/24更新 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/06/24更新 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Riley Hospital for Children at Indiana University Health, Indianapolis
被験者募集中第4相
6歳〜17歳 · 全性別 · 2026/05/27更新 · NCT05781152Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
被験者募集中第2/3相
6歳〜22歳 · 全性別 · 2026/05/05更新 · NCT05660746ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。